4503 Astellas Pharma Inc. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4503

TSE Prime

Astellas Pharma Inc.

1,458.0

JPY

+19.0

(+1.32%)

May 2, 3:30 pm JST

10.04

USD

May 2, 2:30 am EDT

Result

PTS

outside of trading hours

1,457.9

May 2, 11:23 pm JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2022	1,296,163	155,686	156,886	124,086	67.1	50	Apr 27, 2022	IFRS
Mar, 2023	1,518,619	133,029	132,361	98,714	54.2	60	Apr 27, 2023	IFRS
Mar, 2024	1,603,672	25,518	24,969	17,045	9.5	70	Apr 25, 2024	IFRS
Mar, 2025	1,912,323	41,039	31,237	50,747	28.4	74	Apr 25, 2025	IFRS
Mar, 2026 Guidance	1,930,000	160,000	150,000	130,000	72.6	78	Apr 25, 2025	IFRS
YoY	+0.9%	+289.9%	+380.2%	+156.2%	+156.1%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2021	May 14, 2020	1,282,000	252,000	251,000	202,000	42	IFRS
	Aug 4, 2020	1,256,500	246,500	245,500	197,500	42	IFRS
	Oct 30, 2020	1,256,500	210,500	209,500	169,500	42	IFRS
Results	Apr 27, 2021	1,249,528	136,051	145,324	120,589	42	IFRS
Mar, 2022	Apr 27, 2021	Available in future release
	Jul 30, 2021
	Oct 29, 2021
Results	Apr 27, 2022
Mar, 2023	Apr 27, 2022
	Oct 31, 2022
	Feb 6, 2023
	Apr 11, 2023
Results	Apr 27, 2023
Mar, 2024	Apr 27, 2023
	Aug 1, 2023
	Nov 1, 2023
	Feb 5, 2024
	Apr 12, 2024
Results	Apr 25, 2024
Mar, 2025	Apr 25, 2024
	Oct 30, 2024
	Jan 24, 2025
Results	Apr 25, 2025
Mar, 2026	Apr 25, 2025	1,930,000	160,000	150,000	130,000	78	IFRS

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2001	457,913	+5.6	Available in future release
Mar, 2002	481,327	+5.1
Mar, 2003	506,602	+5.3
Mar, 2004	511,207	+0.9
Mar, 2005	447,051	-12.5
Mar, 2006	879,361	+96.7
Mar, 2007	920,624	+4.7
Mar, 2008	972,586	+5.6
Mar, 2009	965,698	-0.7
Mar, 2010	974,877	+1.0
Mar, 2011	953,947	-2.1
Mar, 2012	969,387	+1.6
Mar, 2013	1,005,611	+3.7
Mar, 2014	1,139,909	+13.4
Mar, 2015	1,247,259	+9.4
Mar, 2016	1,372,706	+10.1
Mar, 2017	1,311,665	-4.4
Mar, 2018	1,300,316	-0.9
Mar, 2019	1,306,348	+0.5
Mar, 2020	1,300,843	-0.4
Mar, 2021	1,249,528	-3.9
Mar, 2022	1,296,163	+3.7
Mar, 2023	1,518,619	+17.2
Mar, 2024	1,603,672	+5.6
Mar, 2025	1,912,323	+19.2
Mar, 2026 Guidance	1,930,000	+0.9	160,000	+289.9	150,000	+380.2	72.6	+155.6

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Mar, 2024	1,603,672	25,518	1.59	1.10	0.57	0.53	9.5
Mar, 2025	1,912,323	41,039	2.15	3.26	1.47	0.55	28.4
Mar, 2026 Guidance	1,930,000	160,000	8.29	8.59	3.89	0.58	72.6

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	1,912,323	275,904	284,193	222,265	115.1
Fiscal Year	Mar, 2025	Mar, 2008	Mar, 2008	Mar, 2019	Mar, 2019

First Half

Result

Guidance History

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Apr - Sep, 2022	762,185	119,891	120,480	96,434	52.9	30	Oct 31, 2022	IFRS
Apr - Sep, 2023	767,138	55,156	56,318	35,810	20.0	35	Nov 1, 2023	IFRS
Apr - Sep, 2024	935,621	93,710	89,042	73,511	41.1	37	Oct 30, 2024	IFRS
Apr - Sep, 2025 Guidance	ー	ー	ー	ー	－	39	Apr 25, 2025	IFRS
YoY	－	－	－	－	－

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Sep, 2022	Apr 27, 2022	ー	ー	ー	ー	30	IFRS
- - - - Results	Oct 31, 2022	762,185	119,891	120,480	96,434	30	IFRS
Sep, 2023	Apr 27, 2023	Available in future release
Results	Nov 1, 2023
Sep, 2024	Apr 25, 2024
Results	Oct 30, 2024
Sep, 2025	Apr 25, 2025	ー	ー	ー	ー	39	IFRS

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Mar, 2023	133,029	243,267	327,767	-84,500	-195,623	376,840	15.34	IFRS
Mar, 2024	25,518	-673,327	172,475	-845,802	614,060	335,687	9.40	IFRS
Mar, 2025	41,039	105,093	194,512	-89,419	-261,367	188,372	5.64	IFRS

Actual Performance and Financial Trends

Historical Performance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2023	1,518,619	133,029	132,361	98,714	54.2	60	Apr 27, 2023	IFRS
Mar, 2024	1,603,672	25,518	24,969	17,045	9.5	70	Apr 25, 2024	IFRS
Mar, 2025	1,912,323	41,039	31,237	50,747	28.4	74	Apr 25, 2025	IFRS
YoY	+19.2%	+60.8%	+25.1%	+197.7%	+198.1%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Apr - Jun, 2023	374,990	45,794	46,850	33,129	18.5	12.2	Aug 1, 2023	IFRS
Jul - Sep, 2023	392,148	9,362	9,468	2,681	1.5	2.4	Nov 1, 2023	IFRS
Oct - Dec, 2023	421,932	18,963	17,312	14,513	8.1	4.5	Feb 5, 2024	IFRS
Jan - Mar, 2024	414,602	-48,601	-48,661	-33,278	-18.6	-11.7	Apr 25, 2024	IFRS
Apr - Jun, 2024	473,124	50,657	50,495	37,603	21.0	10.7	Aug 1, 2024	IFRS
Jul - Sep, 2024	462,497	43,053	38,547	35,908	20.1	9.3	Oct 30, 2024	IFRS
Oct - Dec, 2024	517,408	-116,191	-118,359	-97,660	-54.6	-22.5	Feb 4, 2025	IFRS
Jan - Mar, 2025	459,294	63,520	60,554	74,896	41.8	13.8	Apr 25, 2025	IFRS
YoY	+10.8%	－	－	－	－

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Apr - Jun, 2020	306,969	-8.1	Available in future release
Jul - Sep, 2020	308,511	-2.5
Oct - Dec, 2020	325,427	-3.7
Jan - Mar, 2021	308,621	-1.2
Apr - Jun, 2021	326,143	+6.2
Jul - Sep, 2021	325,523	+5.5
Oct - Dec, 2021	340,627	+4.7
Jan - Mar, 2022	303,870	-1.5
Apr - Jun, 2022	381,791	+17.1
Jul - Sep, 2022	380,394	+16.9
Oct - Dec, 2022	402,180	+18.1
Jan - Mar, 2023	354,254	+16.6
Apr - Jun, 2023	374,990	-1.8
Jul - Sep, 2023	392,148	+3.1
Oct - Dec, 2023	421,932	+4.9
Jan - Mar, 2024	414,602	+17.0
Apr - Jun, 2024	473,124	+26.2
Jul - Sep, 2024	462,497	+17.9
Oct - Dec, 2024	517,408	+22.6
Jan - Mar, 2025	459,294	+10.8	63,520	－	60,554	－	41.8	－

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	517,408	97,253	109,053	87,668	45.1
Fiscal Year	Dec, 2024	Dec, 2007	Dec, 2007	Dec, 2018	Dec, 2018

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Mar, 2023	839.26	61.4	2,456,518	1,507,954	908,158	0.08	Apr 27, 2023	IFRS
Mar, 2024	890.07	44.7	3,569,603	1,595,988	809,400	0.58	Apr 25, 2024	IFRS
Mar, 2025	845.25	45.3	3,339,544	1,513,255	740,939	0.55	Apr 25, 2025	IFRS

Astellas Pharma Inc.(4503) Financial Results